Site icon Asrar Qureshi’s Blogs

Pakistan Pharma Industry SWOT – Part 28 – Asrar Qureshi’s Blog Post #619

Dear Colleagues!  This is Asrar Qureshi’s Blog Post #619 for Pharma Veterans. Pharma Veterans welcome sharing of knowledge and wisdom by Veterans for the benefit of Community at large. Pharma Veterans Blog is published by Asrar Qureshi onWordPress, the top blog site. Please email to asrar@asrarqureshi.com for publishing your contributions here.

Opening Note

February 2022 marked my completing 47 years of working in Pharma Industry. Allah be praised. I am still working. The first half of my working career was spent in Multinational companies, and the latter half in the Local Pharma, making me well-versed with both innovators and generics markets. I also had the opportunity to work in business as well as operations.

My journey of near half century is also the journey of Pharma Industry in Pakistan. Great changes have occurred in this time and a lot could be written about it. In my blogs, which were started about four and a half years ago, I have covered several topics related to Pakistan Pharma Industry. This multi-part series shall do and review the SWOT – Strengths, Weaknesses, Opportunities, Threats – of the Pharma Industry.

STRATEGIES

It is now time to strategize, as this was the purpose of this long exercise.

Strategies are made on these parameters:

We shall follow the same line of thinking.

Strategies Based on Strengths

Short Term/ Mid Term Market-based Strategies

  1. Open New Therapeutic Segments
    1. The market dynamics tell us that having a random assortment of products is not good enough. Product portfolio should be evolved around therapeutic segment. You should find the gaps in your own portfolio, and fill these to reinforce or expand the portfolio.

During the last three decades, sub-specialties have become very well recognized and established. Gastroenterology, Hepatology, Nephrology, Rheumatology etc. are all recent additions which have taken firm roots. Within Pediatrics, sub-specialties’ of cardiology, neurology, nephrology, oncology, hematology etc. are now available in Pakistan. Within surgery and internal medicine, several sub-specialties have emerged successfully. Interventional specializations are also here. It has become therefore necessary to build business around these specialties. It is more focused and learning about sub-segments and penetrating these is more rewarding.

The sum up is that no pharma companies should limit the number of therapeutic segments it operates in. Similarly, no company should limit that it would operate in chronic care or acute care only. All segments must be considered and included to get maximum exposure and business.

To be Continued……

Disclaimer. Most pictures in these blogs are taken from Google Images which does not show anyone’s copyright claim. However, if any such claim is presented, we shall remove the image with suitable regrets.

Exit mobile version